Journal article
Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
- Abstract:
-
The murine monoclonal antibody OKT3 is the best known of the anti-CD3 antibodies used for the prevention and treatment of renal allograft rejection. Use of this antibody is associated with improved graft outcome but it has a number of adverse effects thought to result from the massive release of pro-inflammatory cytokines. It has been postulated that OKT3 causes cytokine release because of cross-linking of CD3 molecules on the cell surface by bivalent anti-CD3 antibodies, such as OKT3, and th...
Expand abstract
Actions
Authors
Bibliographic Details
- Journal:
- Therapeutic immunology
- Volume:
- 1
- Issue:
- 6
- Pages:
- 325-331
- Publication date:
- 1994-12-05
- ISSN:
-
0967-0149
- URN:
-
uuid:11bdd514-56b6-4a39-96c0-48f4eaa14912
- Source identifiers:
-
27817
- Local pid:
- pubs:27817
Item Description
Terms of use
- Copyright date:
- 1994
If you are the owner of this record, you can report an update to it here: Report update to this record